Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) (2016 - 2025)

Neurocrine Biosciences' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at $1.48 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 48.0% year-over-year to $1.48; the TTM value through Dec 2025 reached $4.66, up 41.64%, while the annual FY2025 figure was $4.67, 41.95% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.48 in Q4 2025 per NBIX's latest filing, down from $2.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.04 in Q3 2025 to a low of -$0.79 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.64, with a median of $0.66 recorded in 2024.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 1371.43% in 2022, then plummeted 664.29% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.07 in 2021, then surged by 1371.43% to $0.89 in 2022, then skyrocketed by 64.04% to $1.46 in 2023, then tumbled by 31.51% to $1.0 in 2024, then skyrocketed by 48.0% to $1.48 in 2025.
  • Per Business Quant, the three most recent readings for NBIX's EPS (Weighted Average and Diluted) are $1.48 (Q4 2025), $2.04 (Q3 2025), and $1.06 (Q2 2025).